Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Launched by NANTES UNIVERSITY HOSPITAL · Sep 9, 2020
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
Patients : All children treated by ECMO in the 4 PICUs involved in the study
Measurements : A correlation coefficient between the variations of regional cerebral oxygen saturation (rScO2) as a surrogate of cerebral blood flow and the variations of arterial blood pressure (ABP) is calculated as an index of autoregulation (cerebral oxygenation index (COx), ICM+ software®). CA is monitored either on left (COxl) or both sides. A COx \> 0.3 is considered as critical. Neurological outcome is assessed by the onset of an acute neurologic event (ANE) during the ECMO run.
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • Patients under the age of 18 years treated by ECMO
- Exclusion Criteria :
- • Lack of parental consent
About Nantes University Hospital
Nantes University Hospital, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific exploration with patient care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Nantes University Hospital aims to contribute to the development of effective therapies and interventions that enhance patient outcomes and overall public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nantes, , France
Paris, , France
Paris, , France
Genova, , Italy
Patients applied
Trial Officials
Nicolas JORAM, MD
Principal Investigator
Nantes University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials